PanGenex (PGXC) Launches Sales and Marketing Initiative
TAMPA, Fla. (Business Wire EON) April 30, 2008 --
PanGenex Corporation (Pink Sheets:PGXC) announces that in conjunction
with the acquisition of Calgenex Corporation it is launching a
nationwide marketing program. The initiative is a result of the
involvement of recognized medical experts who assisted in the
development of a “Go to Market”
strategy for PanGenex’s proprietary line of
Calgenex nutraceutical products.
The development of Calgenex’s products
resulted from years of research, funding and testing targeted at soft
tissue calcification in the human body and its effects on health.
Dr. Ronald Caputo, Director of Cardiology Research at St. Joseph’s
Hospital in New York and a Calgenex founder stated, “News
organizations and institutions such as the New England Journal of
Medicine, CNN, BusinessWeek, the American College of Cardiology and
others are reporting on the findings from the University of California
that states that ‘measuring calcium deposits
in the arteries of the heart is a good predictor of future heart disease.’
Several of the drugs discussed in these and other studies have not
necessarily provided the expected benefits to patients according to
recent findings. We believe that Calgenex’s
product Calci-CLEAR™ addresses soft tissue
calcification. Along with their other products such as Omeganol™,
which contains the highest Omega-3 content commercially available,
Calgenex provides patients with natural products that improve wellness,
cardiovascular health and manage cholesterol.”
“With our initial research and development
phase now complete, we are marketing products through physician
resellers, at consumer venues across the Internet and creating further
enhancements to include a seamless web portal for its physician network
due to be completed by June 1st,”
explains Jeff Roman, President and CEO.
Learn More about Dr. Ronald Caputo and St. Joseph’s
Hospital Cardiology Associates at:
http://www.sjhcardiology.org/caputo.html.
About PanGenex Corporation:
PanGenex pursues business opportunities in the nutraceutical and
cardiovascular health industries. The Company has developed and markets
novel, patented or patent pending, condition specific nutraceuticals,
topical over-the-counter (OTC) drugs and personal care products. Healthy
Solutions from Science and Nature. ™
Disclaimer:
Cautionary Statement about Forward-Looking Statements
This press release contains "forward-looking statements," which are
statements related to future, not past, events. In this context, the
forward-looking statements often include statements regarding our goals,
plans, projections and guidance regarding our financial position,
results of operations, market position, pending and potential future
acquisitions and business strategy, and often contain words such as
"expects," "anticipates," "intends," "plans," "believes," "seeks" or
"will." Any such forward-looking statements are not assurances of future
performance and involve risks and uncertainties that may cause results
to differ materially from those set forth in the statements. These risks
and uncertainties include, among other things, (a) general economic and
business conditions, (b) the level of strategic partner incentives, (c)
the future regulatory environment, (d) our cost of financing, (e) our
ability to complete acquisitions and dispositions and the risks
associated therewith, and (f) our ability to retain key personnel. These
factors, as well as additional factors, could affect our forward-looking
statements. We urge you to carefully consider this information. We
undertake no duty to update our forward-looking statements, including
our earnings outlook. Statements regarding product have not been
evaluated by the Food and Drug Administration. The products discussed
are not intended to diagnose, treat, cure or prevent any disease.
Post Comment: Trackback URL: http://eon.businesswire.com/pingpr.php/Q291cC1Ib3JyLVByb2YtRmFsdS1GYWx1LVplcm8=
Bookmark -
Del.icio.us |
Digg |
Furl It |
Spurl |
RawSugar |
Simpy |
Shadows |
Blink It |
My Web
|